Novartis: H2 Pipeline Readouts Matter, But Valuation Leaves Limited Upside
Novartis reported a decline in sales and operating income due to increased competition from U.S. generics. The company's innovative medicines are still driving growth, but the current valuation suggests limited upside. Management's guidance indicates strong execution despite these challenges.
- ▪Novartis experienced a 5% decline in sales and an 11% decline in operating income in Q1.
- ▪The decline was primarily attributed to U.S. generic erosion affecting Entresto and Promacta.
- ▪Despite challenges, innovative medicines continue to support the company's growth.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4910246-novartis-h2-pipeline-readouts-matter-but-valuation-leaves-limited-upside"},"author":{"@type":"Person","name":"Mare Evidence Lab","url":"https://seekingalpha.com/author/mare-evidence-lab"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
